Joshua A. Jacobs

Joshua A. Jacobs, PharmD, PhD

Academic Information

Departments Primary - Internal Medicine , Adjunct - Pharmacotherapy

Divisions: Cardiovascular Medicine

Academic Office Information

Joshua.Jacobs@utah.edu

Board Certification

  • Board of Pharmacy Specialties (Sub: Cardiology Pharmacy)

Education History

Undergraduate University of Toledo College of Pharmacy and Pharmaceutical Sciences
 BPharm
Professional Medical University of Toledo College of Pharmacy and Pharmaceutical Sciences
 PharmD
Residency Intermountain Medical Center
 Resident
Residency Ohio State University Wexner Medical Center
 Resident
Doctoral Training University of Utah Spencer Fox Eccles School of Medicine
 PhD

Selected Publications

Journal Article

  1. Jacobs JA, Greene T, Vanneman ME, Kean J, Carter SJ, Shah KS, Pandey A, Derington CG, Zheutlin AR, Fang J, Stehlik J, Fonarow GC, Bress AP (2026). Time to Quadruple Therapy After Initial Diagnosis of Heart Failure With Reduced Ejection Fraction. JAMA Cardiol, 11(6), 506-514.
  2. Sanuade OA, Addo DK, Smith JD, Carroll AJ, Shimbo D, Talegawkar S, Tucker KL, Jacobs JA, Derington CG, Bress AP (2026). The association of urinary sodium with incident apparent treatment resistant hypertension among African Americans: findings from the Jackson Heart Study. J Hum Hypertens, 40(5), 405-412.
  3. Zheutlin AR, Chaitoff A, Addo D, Jacobs JA, Derington CG, Stulberg EL, Glynn PA, Modenesi B, Cohen JB, Bress AP (2026). Out-of-Pocket Costs and Antihypertensive Medication Use Among Veterans: A Natural Experiment. J Am Heart Assoc, 15(8), e047792.
  4. Cohen JB, Addo DK, Jacobs JA, Greene TH, Xu Y, Picone DS, Shimbo D, Bress AP (2026). Impact of a Smartwatch Hypertension Notification Feature for Population Screening. JAMA, 335(11), 1001-1003.
  5. Derington CG, Tong K, Jacobs JA, Egan BM, King JB, Bress AP, Rodgers A, An J, Bryant KB, Cohen JB, Bellows BK (2026). Patient out-of-pocket costs for antihypertensive single pill combination products with cost caps.(Epub ahead of print). J Hum Hypertens.
  6. Zheutlin AR, Jacobs JA, Bress AP (2025). High-Density Lipoprotein Cholesterol and Statin Use Among U.S. Adults With Intermediate 10-Year Predicted ASCVD Risk. JACC Adv, 4(6 Pt 2), 101725.
  7. Jacobs JA, Hendren NS, Alvarez KS, Stinson LJ, Mathew C, Harms M, Bullock G, Cisowska T, Pan IZ, Terry KJ, Goldstein J, Fang JC, Das S, Carter S (2025). The effect of electronic health record choice architecture on diuretic augmentation choice. J Am Coll Clin Pharm.
  8. Cintron MA, Baumer Y, Pang APS, Aquino Peterson EM, Ortiz-Whittingham LR, Jacobs JA, Sharda S, Potharaju KA, Baez AS, Gutierrez-Huerta CA, Ortiz-Chaparro EN, Collins BS, Mitchell VM, Saurabh A, Mendelsohn LG, Redekar NR, Paul S, Corley MJ, Powell-Wiley TM (2025). Associations between the neural-hematopoietic-inflammatory axis and DNA methylation of stress-related genes in human leukocytes: Data from the Washington, D.C. cardiovascular health and needs assessment. Brain Behav Immun Health, 45, 100976.
  9. Zheutlin AR, Jacobs JA, Niforatos JD, Chaitoff A (2025). Prevalence of prescription medication use that can exacerbate heart failure among US adults with heart failure. Pharmacotherapy, 45(3), 155-160.
  10. Bullock G, Jacobs JA, Carey JR, Pan IZ, Kinsey MS, Sideris K, Kapelios CJ, Stehlik J, Fang JC, Das S, Carter SJ (2025). Patterns of diuretic titration during inpatient management of acute decompensated heart failure. Am Heart J, 282, 30-39.
  11. Jacobs JA, Ayodele I, Bress AP, Sterling MR, Pandey A, Derington CG, Zheutlin AR, Shah KS, Greene SJ, Alhanti B, Blanco R, Fonarow GC (2025). Social Determinants of Health and Disparities in Guideline-Directed Medical Therapy Optimization for Heart Failure. Circ Heart Fail, 18(1), e012357.
  12. Derington CG, Berchie RO, Greene T, Jacobs JA, Moran AE, Xu Y, Narita K, Zheutlin AR, Cohen JB, Shimbo D, Bress AP (2025). Using PREVENT Equations to Compare Intensive vs Standard Systolic Blood Pressure Control for Primary Prevention in SPRINT. J Am Coll Cardiol, 86(17), 1437-1448.
  13. Derington CG, Berchie RO, Mohanty AF, Jacobs JA, Xu Y, King JB, Rethy L, Cushman WC, Zickmund SL, Ho PM, Raghavan S, Cohen JB, Bress AP (2025). First-Line ß-Blocker Use for Hypertension in the Veterans Health Administration. JAMA Netw Open, 8(8), e2529026.
  14. Baumer Y, Tirado BA, Ortiz-Whittingham LR, Baez AS, Gutierrez-Huerta CA, Mendelsohn LG, Saurabh A, Jacobs JA, Andrews MR, Mitchell VM, Collins BS, Jones A, Schwartz DM, Dobrian AD, Stanton MV, Powell-Wiley TM (2025). Loneliness associates with endothelial dysfunction in a community-based cohort: a pilot study and translational approach. NPJ Cardiovasc Health, 2, 28.
  15. Xu Y, Derington CG, Addo DK, He T, Jacobs JA, Mohanty AF, An J, Cushman WC, Ho PM, Bellows BK, Cohen JB, Bress AP (2024). Trends in Initial Antihypertensive Medication Prescribing Among >2.8¿Million Veterans Newly Diagnosed With Hypertension, 2000 to 2019. J Am Heart Assoc, 13(20), e036557.
  16. Zheutlin AR, Jacobs JA, Stamm B, Royan R (2024). Lipoprotein(a) among normotensive patients and risk of incident hypertension. J Clin Hypertens (Greenwich), 26(11), 1313-1317.
  17. Jacobs JA, Carter SJ, Bullock G, Carey JR, Pan IZ, Kinsey MS, Zheutlin AR, Kapelios CJ, Raju S, Fang JC, Shah KS, Bress AP (2024). Optimal Initial Intravenous Loop Diuretic Dosing in Acute Decompensated Heart Failure. JACC Adv, 3(10), 101250.
  18. Jacobs JA, Rodgers A, Bellows BK, Hernandez I, Wang N, Derington CG, King JB, Zheutlin AR, Whelton PK, Egan BM, Cushman WC, Bress AP (2024). Use and Cost Patterns of Antihypertensive Medications in the United States From 1996 to 2021. Hypertension, 81(11), 2307-2317.
  19. Zheutlin AR, Sharareh N, Guadamuz JS, Berchie RO, Derington CG, Jacobs JA, Mondesir FL, Alexander GC, Levitan EB, Safford M, Vos RO, Qato DM, Bress AP (2024). Association Between Pharmacy Proximity With Cardiovascular Medication Use and Risk Factor Control in the United States. J Am Heart Assoc, 13(5), e031717.
  20. Jacobs JA, Derington CG, Zheutlin AR, King JB, Cohen JB, Bucheit J, Kronish IM, Addo DK, Morisky DE, Greene TH, Bress AP (2024). Association Between Self-Reported Medication Adherence and Therapeutic Inertia in Hypertension: A Secondary Analysis of SPRINT (Systolic Blood Pressure Intervention Trial). J Am Heart Assoc, 13(3), e031574.
  21. Mentias A, Keshvani N, Sumarsono A, Desai R, Khan MS, Menon V, Hsich E, Bress AP, Jacobs J, Vasan RS, Fonarow GC, Pandey A (2024). Patterns, Prognostic Implications, and Rural-Urban Disparities in Optimal GDMT Following HFrEF Diagnosis Among Medicare Beneficiaries. JACC Heart Fail, 12(6), 1044-1055.
  22. Jacobs JA, Zheutlin AR, Derington CG, King JB, Pandey A, Bress AP (2023). Glucagon-like peptide-1 receptor agonist and sodium-glucose cotransporter 2 inhibitor use among adults with diabetes mellitus by cardiovascular-kidney disease risk: National Health and Nutrition Examination Surveys, 2015-2020. Am J Prev Cardiol, 17, 100624.
  23. Zheutlin AR, Addo DK, Jacobs JA, Derington CG, Herrick JS, Greene T, Stulberg EL, Berlowitz DR, Williamson JD, Pajewski NM, Supiano MA, Bress AP (2023). Evidence for Age Bias Contributing to Therapeutic Inertia in Blood Pressure Management: A Secondary Analysis of SPRINT. Hypertension, 80(7), 1484-1493.
  24. King JB, Berchie RO, Derington CG, Marcum ZA, Scharfstein DO, Greene TH, Herrick JS, Jacobs JA, Zheutlin AR, Bress AP, Cohen JB (2023). New Users of Angiotensin II Receptor Blocker-Versus Angiotensin-Converting Enzyme Inhibitor-Based Antihypertensive Medication Regimens and Cardiovascular Disease Events: A Secondary Analysis of ACCORD-BP and SPRINT. J Am Heart Assoc, 12(17), e030311.
  25. Zheutlin AR, Jacobs JA, Derington CG, Chaitoff A, Navar AM, Bress AP (2023). Age-based disparities in statin use for primary prevention in US adults: National Health and Nutrition Examination Surveys 2013-2020. J Clin Lipidol, 17(5), 688-693.
  26. King JB, Derington CG, Herrick JS, Jacobs JA, Zheutlin AR, Conroy MB, Cushman WC, Bress AP (2023). Single-Pill Combination Product Availability of the Antihypertensive Regimens Used for Intensive Systolic Blood Pressure Treatment in the Systolic Blood Pressure Intervention Trial. Hypertension, 80(8), 1749-1758.
  27. Derington CG, Bress AP, Herrick JS, Jacobs JA, Zheutlin AR, Berchie RO, Conroy MB, Cushman WC, King JB (2023). Antihypertensive Medication Regimens Used by US Adults With Hypertension and the Potential for Fixed-Dose Combination Products: The National Health and Nutrition Examination Surveys 2015 to 2020. J Am Heart Assoc, 12(11), e028573.
  28. Jacobs JA, Addo DK, Zheutlin AR, Derington CG, Essien UR, Navar AM, Hernandez I, Lloyd-Jones DM, King JB, Rao S, Herrick JS, Bress AP, Pandey A (2023). Prevalence of Statin Use for Primary Prevention of Atherosclerotic Cardiovascular Disease by Race, Ethnicity, and 10-Year Disease Risk in the US: National Health and Nutrition Examination Surveys, 2013 to March 2020. JAMA Cardiol, 8(5), 443-452.
  29. Clark JL, Jacobs JA, Watanabe AH, Catino AB, Dechand JA (2023). Evaluation of Safety and Efficacy of Intravenous Digoxin Loading Doses Based on Ideal Body Weight. Ann Pharmacother, 57(10), 1154-1161.
  30. Cisowska T, Pan IZ, Biskupiak J, Shah KS, Fang JC, Jacobs JA (2022). Metolazone Versus Intravenous Chlorothiazide for Decompensated Heart Failure Sequential Nephron Blockade: A Retrospective Cohort Study. J Card Fail, 28(8), 1367-1371.
  31. Jacobs JA, Pickworth K, Boudoulas KD, Hinkley M, McLaughlin E, Blais D (2019). Outcomes for Cancer Patients with Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Cardiovasc Revasc Med, 20(8), 711-715.

Review

  1. Todd OM, Knight M, Jacobs JA, Derington CG, Sheppard JP, Bress AP (2024). Pharmacologic Treatment of Hypertension in Older Adults. [Review]. Clin Geriatr Med, 40, (4), 629-644.
  2. Osei Baah F, Sharda S, Davidow K, Jackson S, Kernizan D, Jacobs JA, Baumer Y, Schultz CL, Baker-Smith CM, Powell-Wiley TM (2024). Social Determinants of Health in Cardio-Oncology: Multi-Level Strategies to Overcome Disparities in Care: JACC: CardioOncology State-of-the-Art Review. [Review]. JACC CardioOncol, 6, (3), 331-346.
  3. Jacobs JA, Jahangir E, Ryan JJ (2022). Differentiating pulmonary hypertension associated with protein kinase inhibitors. [Review]. Pulm Circ, 12, (2), e12075.
  4. Jacobs JA, Shah RU, Bress AP (2022). Asymptomatic hypertension in the hospital setting: primum non nocere. [Review]. J Hum Hypertens, 36, (9), 781-784.
  5. Mayeux JD, Pan IZ, Dechand J, Jacobs JA, Jones TL, McKellar SH, Beck E, Hatton ND, Ryan JJ (2021). Management of Pulmonary Arterial Hypertension. [Review]. Curr Cardiovasc Risk Rep, 15, (1), 2.
  6. Pickworth KK, Blais D, Bagnola A, Barcelona R, Boyd JM, Brink H, Chilbert M, Galipeau D, Gengler B, Gerlach AT, Hayes C, Jacobs J, Kazmi H, Lavelle R, Lindsley J, Macaulay TE, Militello MA, Orzel L, Patel S, Simone P, Tasca K, Varnado S, Zoubek S (2020). COVID-19 pandemic: Challenges and solutions from the cardiology pharmacist's perspective. [Review]. J Am Coll Clin Pharm, 3, (6), 1138-1146.
  7. Pan IZ, Carey JR, Jacobs JA, Dechand J, Sessions JJ, Sorensen T, Penn BA, Mayeux JD, Hatton ND, Ryan JJ (2020). Transitioning Between Prostanoid Therapies in Pulmonary Arterial Hypertension. [Review]. Front Med (Lausanne), 7, 81.

Commentary

  1. Jacobs JA, Ryan JJ (2021). Clinical uncertainty for the use of rivaroxaban in obesity. J Thromb Haemost, 19(3), 870-871.

Case Report

  1. Burkey BW, Jacobs JA, Aziz H (2017). Temperature Instability in an Infant Treated with Propranolol for Infantile Hemangioma. J Pediatr Pharmacol Ther, 22(2), 124-127.

Editorial

  1. Hill MC, Jacobs JA, Wilcox JE (2025). Revisiting Myocardial Recovery in Anthracycline Cardiomyopathy: Defining the Steps to Success in Contemporary Practice. J Card Fail, 31(9), 1390-1392.